Gene therapy for cancer: What have we done and where are we going?

被引:564
作者
Roth, JA [1 ]
Cristiano, RJ [1 ]
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030
关键词
D O I
10.1093/jnci/89.1.21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gene-based therapies for cancer in clinical trials include strategies that involve augmentation of immunotherapeutic and chemotherapeutic approaches, These strategies include ex vivo and in vivo cytokine gene transfer, drug sensitization with genes for prodrug delivery, and the use of drug-resistance genes for bone marrow protection from high-dose chemotherapy. Inactivation of oncogene expression and gene replacement for tumor suppressor genes are among the strategies for targeting the underlying genetic lesions in the cancer cell, A review of clinical trial results to date, primarily in patients with very advanced cancers refractory to conventional treatments, indicates that these treatments can mediate tumor regression with acceptably low toxicity, Vector development remains a critical area for future research, Important areas for future research include modifying viral vectors to reduce toxicity and immunogenicity, increasing the transduction efficiency of nonviral vectors, enhancing vector targeting and specificity, regulating gene expression, and identifying synergies between gene-based agents and other cancer therapeutics.
引用
收藏
页码:21 / 39
页数:19
相关论文
共 152 条
  • [1] ACSADI G, 1991, NEW BIOL, V3, P71
  • [2] ASHER AL, 1991, J IMMUNOL, V146, P3227
  • [3] ADENOVIRUS-MEDIATED P53 GENE DELIVERY INHIBITS 9L GLIOMA GROWTH IN RATS
    BADIE, B
    DRAZAN, KE
    KRAMAR, MH
    SHAKED, A
    BLACK, KL
    [J]. NEUROLOGICAL RESEARCH, 1995, 17 (03) : 209 - 216
  • [4] BENNETT WP, 1993, CANCER RES, V53, P4817
  • [5] EX-VIVO EXPANSION AND SELECTION OF RETROVIRALLY TRANSDUCED BONE-MARROW - AN EFFICIENT METHODOLOGY FOR GENE-TRANSFER TO MURINE LYMPHO-HEMATOPOIETIC STEM-CELLS
    BERNAD, A
    VARAS, F
    GALLEGO, JM
    ALMENDRAL, JM
    BUEREN, JA
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (01) : 6 - 17
  • [6] IN-VITRO EVIDENCE THAT METABOLIC COOPERATION IS RESPONSIBLE FOR THE BYSTANDER EFFECT OBSERVED WITH HSV TK RETROVIRAL GENE-THERAPY
    BI, WL
    PARYSEK, LM
    WARNICK, R
    STAMBROOK, PJ
    [J]. HUMAN GENE THERAPY, 1993, 4 (06) : 725 - 731
  • [7] MOLECULAR THEMES IN ONCOGENESIS
    BISHOP, JM
    [J]. CELL, 1991, 64 (02) : 235 - 248
  • [8] BLAESE M, 1995, CANCER GENE THER, V2, P291
  • [9] T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS
    BLAESE, RM
    CULVER, KW
    MILLER, AD
    CARTER, CS
    FLEISHER, T
    CLERICI, M
    SHEARER, G
    CHANG, L
    CHIANG, YW
    TOLSTOSHEV, P
    GREENBLATT, JJ
    ROSENBERG, SA
    KLEIN, H
    BERGER, M
    MULLEN, CA
    RAMSEY, WJ
    MUUL, L
    MORGAN, RA
    ANDERSON, WF
    [J]. SCIENCE, 1995, 270 (5235) : 475 - 480
  • [10] TARGETED DELIVERY OF ANTISENSE OLIGONUCLEOTIDES BY MOLECULAR CONJUGATES
    BUNNELL, BA
    ASKARI, FK
    WILSON, JM
    [J]. SOMATIC CELL AND MOLECULAR GENETICS, 1992, 18 (06) : 559 - 569